Elatrolet

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Elatrolet

Quick Facts

Property Description
Active ingredient Amitriptyline (as Amitriptyline hydrochloride)
Form Tablet, Oral solution, Injectable solution
Pharmacological class Tricyclic Antidepressant (TCA)
General purpose Modulating nerve signals for mood stability and pain relief
Origin Synthetic compound

What Type of Medicine is Elatrolet?

Elatrolet, which contains the active pharmaceutical ingredient Amitriptyline, is a synthetic compound officially classified as a Tricyclic Antidepressant (TCA). This medication is available as a prescription-only medicine and represents one of the initial generations of psychoactive drugs developed to modulate nerve function within the central nervous system. The TCA class, characterized by its three-ring chemical structure, is clinically recognized for its efficacy across a range of conditions.

This product is distributed as a single active ingredient product utilizing Amitriptyline hydrochloride. While other brands containing the same INN exist, Elatrolet is provided in multiple dosage forms, including oral solid preparations (tablets), an oral solution, and a sterile injectable solution for Intramuscular injection, thereby accommodating various patient administration needs.


Elatrolet Composition: A First-Generation Antidepressant

The composition of Elatrolet relies on Amitriptyline hydrochloride, a potent tertiary amine known for its capability to affect multiple key neural pathways. It is officially categorized as a first-generation antidepressant, a designation that reflects its long history and established therapeutic use in medicine. This pharmacological class is particularly differentiating due to its activity as a non-selective monoamine reuptake inhibitor.

This classification highlights its primary function of influencing both serotonin and norepinephrine pathways simultaneously, a characteristic that sets it apart from newer, more selective agents. This dual mechanism is utilized in the management of chronic neurological discomfort, a specific clinical need for which TCAs are often relied upon.


What is the General Purpose of Amitriptyline?

The general purpose of Amitriptyline is to modify and stabilize imbalances in neural communication, supporting both emotional health and the management of chronic pain. By modulating the available levels of serotonin and norepinephrine, the medication helps restore stability to nervous system signaling.

This foundational action of modulating nerve signals means the medication is utilized to influence mood and concurrently possesses a strong ability to modify persistent, chronic pain signals, particularly those originating from the nerves. The medication's effect on neural pathways provides generalized relief by dampening excessive pain perception, making it particularly valuable in managing chronic discomfort where nerve communication is implicated.

Regulatory References

  1. World Health Organization
  2. NIH MedlinePlus

What side effects are possible with Elatrolet?

Possible Side Effects and Safety Information

Elatrolet (Amitriptyline) has an officially documented safety profile, with potential side effects classified according to their frequency and the body systems they affect, as established in regulatory documents.

Adverse Reaction Classifications

Side effects are categorized by frequency, allowing for differentiation between frequently observed and rare events:

  • Very Common (ge 1/10): Officially listed effects include drowsiness, dry mouth, tremor, headache, dizziness, constipation, and tachycardia (increased heart rate). These often reflect the medication's effects on the central and autonomic nervous systems.
  • Common (ge 1/100 to < 1/10): Reactions such as orthostatic hypotension (a drop in blood pressure upon standing), weight gain, confusion, and fatigue are documented.
  • Rare (ge 1/10,000 to < 1/1,000): Serious but uncommon effects, including certain arrhythmias, jaundice, and severe blood disorders like agranulocytosis, are noted in official labeling.

These effects are grouped into System-Organ Classes (SOCs), which include the Nervous System, Psychiatric System, Cardiovascular System, and Gastrointestinal System.

Safety Constraints and Special Considerations

The regulatory safety profile includes several key limitations and population-specific notes:

  • Serious Constraints: The medication is contraindicated in individuals with a recent myocardial infarction or severe degrees of heart block. It is also prohibited from co-administration with Monoamine Oxidase Inhibitors (MAOIs).
  • Time-Related Patterns: Official labeling notes that the risk of clinical worsening and the emergence of suicidal ideation are associated with the initial months of therapy or following changes in dosage.
  • Vulnerable Populations: Older adults are specified as being more susceptible to certain effects, such as orthostatic hypotension and anticholinergic symptoms. Use in pediatric patients is generally restricted due to specific safety concerns documented in regulatory texts.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information classifies overdose of Elatrolet (Amitriptyline) as a severe and potentially life-threatening emergency, necessitating immediate medical intervention due to the high risk of serious cardiovascular and neurological complications.

Domain Official Regulatory Statements
Documented Overdose Manifestations Symptoms include CNS depression (somnolence, stupor, coma), seizures, agitation, confusion, and anticholinergic effects like mydriasis (dilated pupils) and urinary retention.
Severe Outcomes The primary life-threatening risks are cardiovascular toxicity, including tachycardia, prolonged QRS interval, severe arrhythmias (ventricular), profound hypotension, and cardiac arrest.
Population-Specific Notes Overdose severity is noted to be increased in elderly patients and poses a severe risk to children, where ingestion of small amounts can be fatal.
Antidote Information No specific antidote is known for Amitriptyline overdose; treatment is confined to supportive measures.

When Immediate Medical Help is Required

For any suspected or confirmed overdose, official guidance requires the individual to seek immediate medical attention or emergency medical care without delay. Hospital monitoring is mandatory, including continuous ECG (electrocardiogram) observation to detect and manage cardiotoxicity. Officially documented supportive procedures include the use of activated charcoal and sodium bicarbonate to manage the cardiotoxic effects, such as QRS widening.

Therapeutic Uses of Elatrolet

What Elatrolet Treats: Main Uses and Benefits

The main therapeutic utility of Elatrolet (Amitriptyline) is relevant across two primary therapeutic domains: assisting with the management of chronic physical discomfort and supporting general well-being during symptomatic phases. The medication is utilized to help patients manage distressing symptoms across these key areas.

The therapeutic applications include providing support for Major Depressive Illness, addressing chronic neuropathic pain (such as diabetic or postherpetic neuralgia), and serving as a prophylactic therapy for recurrent headaches (migraine prevention).

Elatrolet is applied where additional symptomatic support is needed for chronic, long-standing pain that creates functional strain, such as the burning, shooting, or stabbing pain associated with nerve damage. This application provides support that helps ease the overall symptom burden and contributes to easing distress when pain interferes with daily functioning. In its role supporting mood, it may help patients cope more steadily when symptoms of depression are more noticeable.

Quick Fact: Relief for Chronic Neuropathic Pain

Eligibility and Restrictions for Use

Who Can and Cannot Use Elatrolet?

Elatrolet (Amitriptyline) is a prescription medication whose eligibility is strictly defined by regulatory guidelines, determining which populations are approved and which are prohibited from use.

Populations Prohibited from Use (Contraindications)

Elatrolet must not be used in patients with an absolute contraindication, as documented by official prescribing information. These typically include:

  • A known hypersensitivity to Amitriptyline or any component of the product.
  • The acute recovery phase following a myocardial infarction (heart attack).
  • Severe liver disease or pre-existing cardiac conduction disorders (such as heart block).
  • Concurrent use with Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of stopping/starting an MAOI.
  • Children under 6 years of age.

Age and Conditional Eligibility

Population Group Official Eligibility Status
Adults (18+) Use generally approved for all labeled indications.
Adolescents (12–17) Use generally limited to Major Depressive Illness under specialist supervision.
Older Adults (65+) Use permitted, but treatment requires initiating a lower starting dose and close monitoring.

Pregnancy and Comorbidity Restrictions

Use is not recommended during pregnancy or breastfeeding unless the potential maternal benefit significantly outweighs the documented risk to the child. Additionally, caution is required for patients with a history of seizures, narrow-angle glaucoma, hyperthyroidism, or severe renal impairment, where the condition may necessitate close monitoring or dose adjustment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Elatrolet documents several categories of interactions that impose strict constraints on co-administration. This information is derived from official government prescribing documents.

Prohibited Combinations

Co-administration is strictly contraindicated with Monoamine Oxidase Inhibitors (MAOIs), including non-psychiatric agents such as Linezolid and Intravenous Methylene Blue, due to the critical risk of Serotonin Syndrome. Combination with Cisapride is also prohibited because of the potential for increased cardiac arrhythmia risk.

Metabolic and Exposure Alteration

Elatrolet's clearance depends on hepatic enzymes, primarily CYP2D6. Co-medication with strong CYP2D6 inhibitors may result in a higher than expected plasma concentration of Elatrolet. This effect necessitates caution, particularly in populations like elderly patients or those with severe liver disease where clearance is impaired.

Pharmacodynamic Effects

Co-administration with other serotonergic agents or St. John's Wort increases the general risk of Serotonin Syndrome. The effects of Alcohol and other CNS depressants are enhanced, resulting in heightened sedative effects. Additive effects also occur with anticholinergic agents and drugs that prolong the QTc interval.

Administration Requirements

A minimum 14-day period must pass between discontinuing an irreversible MAOI and starting Elatrolet, and vice-versa. Food consumption may slow the rate of absorption of the medicine.

Mechanism of Action

How Elatrolet Works

Elatrolet's mechanism of action is multifaceted, relying on simultaneous engagement with three primary biological domains to stabilize and dampen excessive nerve signaling across the central and peripheral nervous systems.


Modulating Descending Monoamine Pathways

This primary mechanism involves the non-selective blockade of the Serotonin ( SERT) and Norepinephrine ( NET) transporters. By preventing the reuptake of these two key neurotransmitters, the compound enhances their concentration and signaling strength in the spinal cord, which potentiates the descending inhibitory pathways responsible for influencing the signal transduction of pain-related pathways.


Stabilizing Nerves via Voltage-Gated Sodium Channel Blockade

This compound acts independently of its monoamine effects by directly blocking Voltage-Gated Sodium Channels ( VGSCs) in neuronal membranes. This action stabilizes the electrical properties of the nerve cell, preventing the rapid ion influx necessary for initiating an impulse, and inhibits the propagation of abnormal, ectopic action potentials associated with dysregulated neuronal excitability.


Non-Selective Binding and Central Arousal Reduction

Elatrolet also binds to and antagonizes several other receptors, notably the Histamine H1 and Muscarinic M1 receptors. Blocking H1 receptors in the CNS is the mechanism that results in immediate inhibition of histaminergic arousal pathways, leading to a state of reduced CNS activity, while the other binding contributes to the overall non-selective physiological profile that influences the mechanistic constraints of the compound.

Dosage and Administration Information

How to Use Elatrolet: Official Administration Guidelines

Elatrolet (Amitriptyline) must be used strictly according to the official instructions provided to ensure standardized application. The procedural structure focuses on safe initiation and gradual adjustment over the course of treatment.


Approved Administration and Dosing

Elatrolet is approved for administration via the oral route (tablets or solution) and, in specific circumstances, the intramuscular (IM) route for hospitalized patients unable to take oral forms.

Standard Adult Dosing Regimens (Oral)

Indication Initial Dose (Outpatient) Maximum Daily Dose Frequency
Depression 75 mg/day (divided or single bedtime dose) 150 mg/day (Outpatient) Once daily or divided doses
Neuropathic Pain 10 mg to 25 mg in the evening 75 mg/day (Dosing varies) Once daily (evening/bedtime)

Procedural Instructions

  • Titration: Treatment must begin at a low starting dose and be increased gradually (e.g., in 25 mg increments) based on professional assessment, with preference for adjusting the bedtime dose.
  • Timing: The daily dose is preferably administered as a single dose at bedtime due to the medicine's properties, and tablets may be taken with or without food.
  • Duration: For depression, maintenance therapy should continue for at least three months after improvement. Treatment must be gradually withdrawn (tapered) upon discontinuation.
  • Special Populations: Lower starting doses (e.g., total 50 mg/day) and slower titration are indicated for older adults (geriatric patients) and those with impaired liver function. The medicine should be used with caution in patients with liver function impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Elatrolet

This section summarizes the structure of the clinical research supporting the established applications of Elatrolet (Amitriptyline), drawn from authoritative regulatory documents and peer-reviewed systematic reviews.


Evidence for Use in Major Depressive Illness

Elatrolet was studied for Major Depressive Disorder (MDD) through numerous Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews. This research, focused on adult populations, examined outcomes related to physiological strain or stress by measuring changes on depression rating scales, typically over short-term intervals of 3 to 12 weeks. Studies report how symptoms evolved in the observed populations during periods of increased symptom activity. Long-term effects are not fully established beyond the acute phase, and older trials often had unclear reporting regarding specific methodological elements.


Evidence for Use in Chronic Neuropathic Pain

Research examined chronic pain conditions, such as painful diabetic neuropathy and postherpetic neuralgia, using Systematic Reviews and Meta-analyses that combine smaller-scale RCTs. This evidence was observed in adult populations, exploring patient-reported outcomes describing perceived discomfort, such as pain intensity scores. Studies report how symptoms evolved in the observed populations when compared to control groups, contributing to understanding symptom patterns. Sample sizes were modest in individual trials, and results apply only to the populations studied, with limited information available for certain older adult populations.


Evidence for Use in Migraine Prevention

Research was studied for the prophylaxis (prevention) of recurrent headaches in adult populations. Studies monitored outcomes describing episodic or acute changes, primarily focusing on the measured change in the frequency of headaches, such as the number of migraine days reported per month. Research highlights changes measured during the study period. The evidence quality varies across studies, and some reviews note low certainty. Research exploring Elatrolet in migraine prevention in children remains limited.


Long-Term Research and Durability of Response

Research has explored short-term symptom changes but long-term effects are not fully established across the main applications. For both pain and migraine, controlled research generally provides limited information for long-term outcomes regarding the sustained stability of symptom patterns.


What Remains Uncertain About the Research

Research contributes to the broader evidence landscape, but also highlights areas where certainty remains low or data is incomplete. Subgroup findings are uncertain, as studies often lack the sample size to provide precise information. This means research provides context but not personal outcomes; study results reflect the specific conditions under which they were conducted.

Key Studies & References A Comparative Systematic Review and Meta-analysis of Amitriptyline with Propranolol and Flunarizine for the Prophylaxis of Migraine Headache

Frequently Asked Questions (FAQ)

Common questions about Elatrolet (FAQ)


Q: What is the main difference between Elatrolet and other similar drugs for the same condition?

A: Elatrolet contains the active ingredient Amitriptyline, which is officially classified as a Tricyclic Antidepressant (TCA). This older class of medicine works by increasing the brain’s levels of both norepinephrine and serotonin, setting it apart from newer agents like SSRIs, which primarily target only serotonin.

Q: Does Elatrolet affect sleep?

A: Official product information lists drowsiness and sedation as very common effects. Regulatory guidelines often recommend taking the daily dose at bedtime, partly due to the medicine’s sedating properties.

Q: How quickly does Elatrolet typically start working?

A: The effects can be perceived differently depending on the purpose of use. The sedative effect may be apparent early on, but the full antidepressant effect may require up to 30 days or more to fully manifest, as noted in official prescribing information.

Q: Can I take vitamins or supplements while on Elatrolet?

A: The official label notes a specific interaction with the herbal supplement St. John’s wort, which can increase serotonin levels. Patients are generally advised in product information to discuss all vitamins, herbal remedies, and supplements with their healthcare provider.

Q: Is it okay to drink a small amount of alcohol while taking Elatrolet?

A: Official safety constraints note that the combination of Elatrolet and alcohol can alter the effects of the medicine and cause increased side effects, such as heightened sedation. Patients are advised to generally avoid alcohol because of the potential for enhanced side effects.

Q: Does Elatrolet have potential long-term effects on the liver?

A: Adverse events documented in official labeling include abnormalities in liver function tests. These effects are typically mild and transient (temporary) and generally reverse once the medication is stopped. Severe liver disease is noted as a contraindication.

Q: How often should follow-up appointments be scheduled when taking Elatrolet?

A: Official regulatory warnings concerning the emergence of clinical worsening and suicidal ideation in certain young adults mandate close monitoring for all patients. This close observation is considered particularly important during the initial months of therapy or following dosage changes.

Q: Is Elatrolet safe to take every day for a long time?

A: Official guidelines indicate that treatment for major depressive illness should continue for at least three months after improvement. If the medication is discontinued after long-term use, official guidelines state it should be gradually withdrawn to help manage the risk of withdrawal symptoms.

Q: Can Elatrolet cause weight changes?

A: Yes, regulatory documents list weight gain as a common side effect of this medicine. This effect is generally associated with the compound’s antihistamine properties.

Q: Are there any common foods or drinks that interact with Elatrolet?

A: The medicine can be taken with or without food. Official information notes that food consumption may slow the rate of absorption of the medicine, which could delay the onset of some effects.

Q: Is it true that Elatrolet requires regular monitoring/tests?

A: Yes, official documents recommend close monitoring of a patient's cardiovascular status, including ECG changes. Additionally, testing for certain liver enzymes (like CYP2D6) may be used to help guide the correct dosage.

Q: Is Elatrolet a narcotic or habit-forming medicine?

A: Elatrolet is not classified as a narcotic or a controlled substance by the DEA (Drug Enforcement Administration). It belongs to the pharmacological class of Tricyclic Antidepressants.

Q: How is Elatrolet eliminated from the body?

A: Elatrolet is processed in the liver by specific enzymes, such as CYP2D6 and CYP2C19. Once metabolized (broken down), the medicine and its inactive components are primarily excreted through the urine.

Q: Why do some patients feel better right away on Elatrolet and others don't?

A: Official information indicates that the sedative effect of the medicine is often felt before the therapeutic effect on mood or chronic discomfort. Patient response can also be affected by genetic differences in how the liver enzymes metabolize the standard dose.

Q: Why is Elatrolet often prescribed over other treatments?

A: While FDA-approved for depression, Elatrolet is used in clinical practice for managing conditions like chronic nerve pain and for migraine prevention. Its ability to influence multiple nerve signaling pathways is considered beneficial for managing those specific symptoms, according to general consensus and study themes.

Q: What are the official guidelines regarding stopping Elatrolet?

A: Regulatory guidelines emphasize that treatment must be gradually withdrawn (tapered) upon discontinuation. Abruptly stopping the medicine after long-term use is associated with the risk of withdrawal symptoms.

Q: What are the signs of a serious side effect from Elatrolet?

A: Official safety information notes that medical attention is warranted if signs of serious heart problems are experienced. These include chest pain, shortness of breath, fainting, or irregular or pounding heartbeats, as documented in official safety information.

Q: Can Elatrolet affect my ability to drive or operate machinery?

A: Due to the medicine's potential for causing sedation and drowsiness, official warnings state that activities requiring mental alertness should be avoided while using the medicine. This includes driving or operating heavy machinery.

Q: What is the stability of Elatrolet if exposed to heat?

A: Official storage instructions mandate that Elatrolet tablets must be kept at a Controlled Room Temperature, specifically defined as 20 C to 25 C (68 F to 77 F). Exposure to temperatures outside this range may affect the product's stability.

Q: Does the time of day I take Elatrolet matter?

A: Regulatory administration instructions note that the daily dose is preferably administered as a single dose at bedtime. This timing is recommended because the medicine’s properties can cause sedation and drowsiness.

Q: What are common user experiences reported when starting Elatrolet?

A: Common initial experiences include drowsiness, dry mouth, tremor, and headache, as listed in the Very Common side effect category. While sedation is often perceived quickly, the full therapeutic benefit may take several weeks to appear.

Q: Why is Elatrolet not recommended for people with a history of certain conditions?

A: The medicine is contraindicated or requires extreme caution for specific patient groups due to known risks. For example, it is not recommended for people with severe heart problems because it can affect cardiac conduction.

Q: What if I start taking a new prescription after starting Elatrolet?

A: Numerous drugs can interact with Elatrolet, potentially affecting serotonin levels or how the medicine is metabolized. Patients are generally advised in official documents to inform their provider of all new medications so that potential major interactions can be checked.

Q: Does Elatrolet affect birth control pills?

A: Regulatory documents concerning drug interactions suggest that certain oral contraceptives may increase the serum concentration of Elatrolet. This effect is thought to be due to the pills inhibiting the medicine's metabolism in the liver.

Q: How is Elatrolet dosed for different patient ages or weights?

A: Official dosing guidelines indicate that older adults (geriatric patients) and adolescents typically require a lower starting dose and slower titration (gradual adjustment) compared to the general adult dosage to manage potential side effects.

How should Elatrolet be stored and disposed of?

How to Store and Dispose of Elatrolet

Elatrolet (Amitriptyline) must be stored according to regulatory requirements to ensure its stability. Tablets must be kept at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product requires storage in a tight, light-resistant container and must be kept in a cool, dry area. It is mandatory to keep the medication out of the sight and reach of children and store it securely.

For disposal, the product must not be thrown into wastewater or household drains due to its toxicity to aquatic life. Unused or expired medication should be disposed of through an authorized drug take-back program. If a program is unavailable, mix the medicine with an undesirable substance, seal it, and place it in the household trash, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Elatrolet found in:

A-Z Index: